SOURCE: DNAPrint Genomics, Inc.

August 24, 2006 07:00 ET

/ CORRECTION - DNAPrint Genomics, Inc.

SARASOTA, FL -- (MARKET WIRE) -- August 24, 2006 -- In the news release, "DNAPrint Genomics Announces Strategic Alliance With NeoCodex," issued Tuesday, August 22, 2006, by DNAPrint Genomics, Inc. (OTCBB: DNAG), we are advised by the company that the subheadline should read "NeoCodex to Provide DNA Sample Testing for Theranostic Research on Ovarian Cancer" rather than "Company Will Provide DNA Sample Testing for Theranostic Research on Ovarian Cancer" as originally issued. Additionally, the fifth paragraph has been added to represent a quote from Enrique Vazquez, President and CEO of NeoCodex. Complete corrected text follows.

DNAPrint Genomics Announces Strategic Alliance With NeoCodex

NeoCodex to Provide DNA Sample Testing for Theranostic Research on Ovarian Cancer

SARASOTA, FL -- August 22, 2006 -- DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that it has signed a strategic alliance agreement with NeoCodex, Inc., of Sevilla, Spain, to provide DNA sampling for ongoing research into theranostic test/drug treatments for ovarian cancer.

Under the terms of the agreement, NeoCodex business units in Spain and in the United States will gather DNA samples that will be tested by DNAPrint Genomics for research into the effectiveness of certain treatments for ovarian cancer involving combinatorial treatments of Taxotere®, Taxol®, Carboplatin, and Cisplatin.

DNAPrint technologies will apply its Admixture Mapping (ADMIX) process to identify appropriate Ancestry Informative Markers (AIMs) within the targeted population to identify genes of further interest, based on the drug response data provided by NeoCodex.

"We are extremely pleased to collaborate with NeoCodex on this important research," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "A crucial element of any chemotherapy regimen is identifying immediately the combinations of drugs that will put the cancer into remission. We are confident that our tests, which use specific DNA markers to anticipate the effectiveness of particular drugs on a patient, when fully developed and offered to the market, will establish a world standard for theranostic testing and help alleviate the suffering of cancer patients worldwide."

Enrique Vazquez, President and CEO of NeoCodex added, "We are excited by the potential that our unique sample set brings to DNAPrint's platform. We believe the combination of highly-annotated, longitudinally collected samples coupled with DNAPrint's ADMIX process will accelerate theranostic research and bring us one step closer to true personalized medicine."

About NeoCodex, Inc.

NeoCodex SL is a biomedical and genomic research 'total solutions provider,' focused on understanding the molecular and genetic basis of human disease, and on employing novel methodologies for the continued improvement of current genetic analysis techniques. Additionally equipped to provide a wide-range of DNA specimens from internally-maintained biological repositories and from prospective collections, NeoCodex remains a leader in the research and support service arenas. For further information, contact Kathleen Bem at 317-727-5962.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS™, RETINOME™, ANCESTRYbyDNA™ and EURO-DNA™. DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Contact Information

  • Company Contact:

    Richard Gabriel
    CEO and President
    941 366-3400

    or

    Ron Stabiner
    The Wall Street Group, Inc.
    212-888-4848